Autoimmune hemolytic anemia pathophysiology: Difference between revisions
Jump to navigation
Jump to search
Shyam Patel (talk | contribs) |
Iqra Qamar (talk | contribs) |
||
| (9 intermediate revisions by 3 users not shown) | |||
| Line 2: | Line 2: | ||
{{Autoimmune hemolytic anemia}} | {{Autoimmune hemolytic anemia}} | ||
{{CMG}} '''Assosciate Editor(s)-In-Chief:''' [[User: Prashanthsaddala|Prashanth Saddala M.B.B.S]]; {{shyam}} | {{CMG}} '''Assosciate Editor(s)-In-Chief:''' [[User: Prashanthsaddala|Prashanth Saddala M.B.B.S]]; {{shyam}}, [[User:Irfan Dotani|Irfan Dotani]] [3] | ||
==Overview== | ==Overview== | ||
The pathophysiology of autoimmune hemolytic anemia is different for warm-antibody type and cold-antibody type anemia. The pathophysiology of warm-antibody type autoimmune hemolytic anemia involves the coating of [[Red blood cell|red blood cells]] with [[IgG]], followed by extravascular hemolysis by [[splenic]] [[macrophages]]. The pathophysiology of cold-antibody type autoimmune hemolytic anemia involves the coating of red blood cells with IgM, followed by intravascular hemolysis. The [[complement system]] has a significant role in autoimmune hemolytic anemia and involves the binding of classical complement proteins on the [[red blood cell]] surface, followed by [[cell lysis]] by the [[membrane attack complex]]. In summary, a variety of cell-mediated immunologic mechanisms underlie the pathophysiology of autoimmune hemolytic anemia. | |||
==Pathophysiology== | ==Pathophysiology== | ||
===Warm autoimmune hemolytic anemia=== | ===Warm autoimmune hemolytic anemia=== | ||
The pathophysiology of warm autoimmune hemolytic anemia involves immunoglobulin G (IgG) antibodies binding to [[red blood cells]] at a temperature of 37 degrees Celsius. <ref name="pmid15637139">{{cite journal| author=Mqadmi A, Zheng X, Yazdanbakhsh K| title=CD4+CD25+ regulatory T cells control induction of autoimmune hemolytic anemia. | journal=Blood | year= 2005 | volume= 105 | issue= 9 | pages= 3746-8 | pmid=15637139 | doi=10.1182/blood-2004-12-4692 | pmc=1895013 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15637139 }} </ref> The designation of ''warm'' is based on the fact the optimal binding temperature is 37 degrees Celsius, or normal body temperature. The IgG antibodies are typically polyclonal, meaning that they recognize a variety of antigens.<ref name="pmid26696798">{{cite journal| author=Berentsen S| title=Role of Complement in Autoimmune Hemolytic Anemia. | journal=Transfus Med Hemother | year= 2015 | volume= 42 | issue= 5 | pages= 303-10 | pmid=26696798 | doi=10.1159/000438964 | pmc=4678321 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26696798 }} </ref> Macrophages bind to the antibody-coated [[red blood cells]] via the Fc receptors and result in extravascular destruction. The Fc receptors include Fc-gammaRI (CD64), Fc-gammaRII (CD32), and Fc-gammaRIII (CD16). In 15-20% of cases, the autoantibody involved | The pathophysiology of warm autoimmune hemolytic anemia involves [[immunoglobulin G]] ([[IgG]]) antibodies binding to [[red blood cells]] at a temperature of 37 degrees Celsius. <ref name="pmid15637139">{{cite journal| author=Mqadmi A, Zheng X, Yazdanbakhsh K| title=CD4+CD25+ regulatory T cells control induction of autoimmune hemolytic anemia. | journal=Blood | year= 2005 | volume= 105 | issue= 9 | pages= 3746-8 | pmid=15637139 | doi=10.1182/blood-2004-12-4692 | pmc=1895013 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15637139 }} </ref> The designation of ''warm'' is based on the fact the optimal binding temperature is 37 degrees Celsius, or normal body temperature. The IgG antibodies are typically [[polyclonal]], meaning that they recognize a variety of [[antigens]].<ref name="pmid26696798">{{cite journal| author=Berentsen S| title=Role of Complement in Autoimmune Hemolytic Anemia. | journal=Transfus Med Hemother | year= 2015 | volume= 42 | issue= 5 | pages= 303-10 | pmid=26696798 | doi=10.1159/000438964 | pmc=4678321 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26696798 }} </ref> [[Macrophages]] bind to the antibody-coated [[red blood cells]] via the Fc receptors and result in extravascular destruction. The Fc receptors include Fc-gammaRI ([[CD64 (biology)|CD64]]), Fc-gammaRII ([[CD32]]), and Fc-gammaRIII ([[CD16]]). In 15-20% of cases, the autoantibody involved is IgA.<ref name="pmid26696798">{{cite journal| author=Berentsen S| title=Role of Complement in Autoimmune Hemolytic Anemia. | journal=Transfus Med Hemother | year= 2015 | volume= 42 | issue= 5 | pages= 303-10 | pmid=26696798 | doi=10.1159/000438964 | pmc=4678321 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26696798 }} </ref> It has been shown that induction of autoimmune hemolytic anemia is controlled by an [[Immunosuppression|immunosuppressive]] population of [[T lymphocytes]] known as [[regulatory T cells]].<ref name="pmid15637139">{{cite journal| author=Mqadmi A, Zheng X, Yazdanbakhsh K| title=CD4+CD25+ regulatory T cells control induction of autoimmune hemolytic anemia. | journal=Blood | year= 2005 | volume= 105 | issue= 9 | pages= 3746-8 | pmid=15637139 | doi=10.1182/blood-2004-12-4692 | pmc=1895013 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15637139 }} </ref> | ||
===Cold autoimmune hemolytic anemia=== | ===Cold autoimmune hemolytic anemia=== | ||
The pathophysiology of cold autoimmune hemolytic anemia, or [[cold agglutinin disease]], involves immunoglobulin | The pathophysiology of cold autoimmune hemolytic anemia, or [[cold agglutinin disease]], involves [[immunoglobulin M]] ([[IgM]]) antibodies binding to ''Ii'' carbohydrate antigens of [[red blood cells]] at a temperature of 3-5 degrees Celcius. [[Agglutination]] typically occurs in the distal aspects of the extremities, such as the fingers and toes, because these areas have the lowest temperature.<ref name="pmid25705656">{{cite journal| author=Berentsen S, Sundic T| title=Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy. | journal=Biomed Res Int | year= 2015 | volume= 2015 | issue= | pages= 363278 | pmid=25705656 | doi=10.1155/2015/363278 | pmc=4326213 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25705656 }} </ref> Clinical manifestations of this pathophysiology includes [[Raynaud's phenomenon]] and [[acrocyanosis]].<ref name="pmid25705656">{{cite journal| author=Berentsen S, Sundic T| title=Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy. | journal=Biomed Res Int | year= 2015 | volume= 2015 | issue= | pages= 363278 | pmid=25705656 | doi=10.1155/2015/363278 | pmc=4326213 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25705656 }} </ref> The IgM molecules will trigger activation of the [[complement]] system, which results in [[red blood cell]] lysis.<ref name="pmid25705656">{{cite journal| author=Berentsen S, Sundic T| title=Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy. | journal=Biomed Res Int | year= 2015 | volume= 2015 | issue= | pages= 363278 | pmid=25705656 | doi=10.1155/2015/363278 | pmc=4326213 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25705656 }} </ref> When IgM-bound [[red blood cells]] circulate towards warmer areas of the body, such as the trunk, [[IgM]] will dissociate from the [[red blood cells]] and [[complement]] C3b will remain bound. | ||
===Role of the complement system=== | ===Role of the complement system=== | ||
The complement system is partially involved in the pathophysiology of warm autoimmune hemolytic anemia. There is a stronger role for the complement system in certain types of autoimmune hemolytic anemia, such as paroxysmal cold hemoglobinuria, cold agglutinin disease, and cold agglutinin syndrome.<ref name="pmid25705656">{{cite journal| author=Berentsen S, Sundic T| title=Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy. | journal=Biomed Res Int | year= 2015 | volume= 2015 | issue= | pages= 363278 | pmid=25705656 | doi=10.1155/2015/363278 | pmc=4326213 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25705656 }} </ref> The complement system plays a role in both | The [[complement]] system is partially involved in the pathophysiology of warm autoimmune hemolytic anemia. There is a stronger role for the complement system in certain types of autoimmune hemolytic anemia, such as [[paroxysmal cold hemoglobinuria]], [[cold agglutinin disease]], and [[cold agglutinin syndrome]].<ref name="pmid25705656">{{cite journal| author=Berentsen S, Sundic T| title=Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy. | journal=Biomed Res Int | year= 2015 | volume= 2015 | issue= | pages= 363278 | pmid=25705656 | doi=10.1155/2015/363278 | pmc=4326213 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25705656 }} </ref> The complement system plays a role in both extravascular hemolysis and intravascular hemolysis in [[autoimmune hemolytic anemia]]. | ||
*'''Complement activation by immunoglobulin subclasses''': The immunoglobulin type that is most potent in activating complement is immunoglobulin M (IgM). However, IgM is not typically detected in the [[Coombs' test]], so IgM-mediated hemolysis will likely manifest as a Coombs'-negative hemolytic anemia. Immunoglobulin G (IgG) can activate complement, and the different IgG subclasses have differentially ability to activate complement. IgG3, for example, is a more potent activator of complement than IgG1. IgG4 and immunoglobulin A (IgA) are unable to activate complement.<ref name="pmid25705656">{{cite journal| author=Berentsen S, Sundic T| title=Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy. | journal=Biomed Res Int | year= 2015 | volume= 2015 | issue= | pages= 363278 | pmid=25705656 | doi=10.1155/2015/363278 | pmc=4326213 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25705656 }} </ref> | *'''Complement activation by immunoglobulin subclasses''': The immunoglobulin type that is most potent in activating complement is [[immunoglobulin M]] (IgM). However, [[IgM]] is not typically detected in the [[Coombs test|Coombs' test]], so IgM-mediated hemolysis will likely manifest as a Coombs'-negative hemolytic anemia. Immunoglobulin G (IgG) can activate complement, and the different IgG subclasses have differentially ability to activate complement. IgG3, for example, is a more potent activator of complement than IgG1. IgG4 and immunoglobulin A (IgA) are unable to activate complement.<ref name="pmid25705656">{{cite journal| author=Berentsen S, Sundic T| title=Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy. | journal=Biomed Res Int | year= 2015 | volume= 2015 | issue= | pages= 363278 | pmid=25705656 | doi=10.1155/2015/363278 | pmc=4326213 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25705656 }} </ref> | ||
*'''[[Extravascular hemolysis]]''': The pathophysiology of | *'''[[Extravascular hemolysis]]''': The pathophysiology of extravascular hemolysis in autoimmune hemolytic anemia involves destruction of [[red blood cells]] outside the blood vessels and inside the [[liver]] and [[spleen]]. This is largely due to complement protein C3b-mediated [[phagocytosis]] of [[red blood cells]]. This process begins with the [[C3-convertase|C3 convertase]], which leads to production of complement protein C3b. This protein normally functions to [[opsonize]] bacteria and prevent infection, as part of the innate immune system. However, in pathological conditions such as autoimmunity, C3b binds to the surface of [[red blood cells]]. Opsonization by C3b triggers the macrophages of the [[reticuloendothelial system]] to phagocytose these opsonized cells via complement receptors on the surface of macrophages. This [[phagocytosis]] occurs extravascularly, typically in the liver or spleen. In some cases, [[ectoenzymes]] that are located on the surface of macrophages can perforate [[red blood cell]] membranes and create spherocytes.<ref name="pmid25705656">{{cite journal| author=Berentsen S, Sundic T| title=Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy. | journal=Biomed Res Int | year= 2015 | volume= 2015 | issue= | pages= 363278 | pmid=25705656 | doi=10.1155/2015/363278 | pmc=4326213 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25705656 }} </ref> When the amount of [[red blood cell]] membrane removed exceeds the intracellular volume removed, the biconcave disc shape becomes a spherocytic shape. This is the pathophysiologic basis for spherocytes in autoimmune hemolytic anemia.<ref name="pmid25705656">{{cite journal| author=Berentsen S, Sundic T| title=Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy. | journal=Biomed Res Int | year= 2015 | volume= 2015 | issue= | pages= 363278 | pmid=25705656 | doi=10.1155/2015/363278 | pmc=4326213 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25705656 }} </ref> Upon passage through the splenic vasculature, spherocytes can destroyed. | ||
*'''[[Intravascular hemolysis]]''': The pathophysiology of [[intravascular hemolysis]] in autoimmune hemolytic anemia involves destruction of [[red blood cells]] inside the blood vessels. This is largely due to activation of the terminal complement system.<ref name="pmid26696798">{{cite journal| author=Berentsen S| title=Role of Complement in Autoimmune Hemolytic Anemia. | journal=Transfus Med Hemother | year= 2015 | volume= 42 | issue= 5 | pages= 303-10 | pmid=26696798 | doi=10.1159/000438964 | pmc=4678321 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26696798 }} </ref> This complement cascade begins with complement protein C5, which is activated to C5a and C5b by the C5 convertase. C5a is a potent anaphylactic molecule, C5b is a membrane-bound protein that binds to downstream complement molcules, such as C6 though C9. The union of C5b and C6 though C9 forms the membrane attack complex. This complex can exert direct cytotoxic activity via the creation of pores in [[red blood cell]] membranes, resulting in cell lysis intravascularly.<ref name="pmid26696798">{{cite journal| author=Berentsen S| title=Role of Complement in Autoimmune Hemolytic Anemia. | journal=Transfus Med Hemother | year= 2015 | volume= 42 | issue= 5 | pages= 303-10 | pmid=26696798 | doi=10.1159/000438964 | pmc=4678321 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26696798 }} </ref> | *'''[[Intravascular hemolysis]]''': The pathophysiology of [[intravascular hemolysis]] in autoimmune hemolytic anemia involves destruction of [[red blood cells]] inside the blood vessels. This is largely due to activation of the terminal [[complement system]].<ref name="pmid26696798">{{cite journal| author=Berentsen S| title=Role of Complement in Autoimmune Hemolytic Anemia. | journal=Transfus Med Hemother | year= 2015 | volume= 42 | issue= 5 | pages= 303-10 | pmid=26696798 | doi=10.1159/000438964 | pmc=4678321 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26696798 }} </ref> This complement cascade begins with complement protein [[C5]], which is activated to [[C5a]] and [[C5b]] by the C5 convertase. C5a is a potent anaphylactic molecule, C5b is a membrane-bound protein that binds to downstream complement molcules, such as C6 though C9. The union of C5b and C6 though C9 forms the membrane attack complex. This complex can exert direct cytotoxic activity via the creation of pores in [[red blood cell]] membranes, resulting in cell lysis intravascularly.<ref name="pmid26696798">{{cite journal| author=Berentsen S| title=Role of Complement in Autoimmune Hemolytic Anemia. | journal=Transfus Med Hemother | year= 2015 | volume= 42 | issue= 5 | pages= 303-10 | pmid=26696798 | doi=10.1159/000438964 | pmc=4678321 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26696798 }} </ref> | ||
===Excess complement activation=== | ===Excess complement activation=== | ||
In some cases, the complement system can become activated very strongly, resulting in excess immune activation and [[red blood cell]] destruction, which can be lethal. This is due in part to a [[feedforward]] loop or positive feedback system, in which activation of the initial components of the complement cascade triggers activation of additional complement components.<ref name="pmid26696798">{{cite journal| author=Berentsen S| title=Role of Complement in Autoimmune Hemolytic Anemia. | journal=Transfus Med Hemother | year= 2015 | volume= 42 | issue= 5 | pages= 303-10 | pmid=26696798 | doi=10.1159/000438964 | pmc=4678321 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26696798 }} </ref> | * In some cases, the [[complement system]] can become activated very strongly, resulting in excess immune activation and [[red blood cell]] destruction, which can be lethal. This is due in part to a [[feedforward]] loop or positive feedback system, in which activation of the initial components of the [[complement cascade]] triggers activation of additional complement components.<ref name="pmid26696798">{{cite journal| author=Berentsen S| title=Role of Complement in Autoimmune Hemolytic Anemia. | journal=Transfus Med Hemother | year= 2015 | volume= 42 | issue= 5 | pages= 303-10 | pmid=26696798 | doi=10.1159/000438964 | pmc=4678321 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26696798 }} </ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
Latest revision as of 19:51, 22 May 2018
|
Autoimmune hemolytic anemia Microchapters |
|
Differentiating Autoimmune hemolytic anemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune hemolytic anemia pathophysiology On the Web |
|
American Roentgen Ray Society Images of Autoimmune hemolytic anemia pathophysiology |
|
Directions to Hospitals Treating Autoimmune hemolytic anemia |
|
Risk calculators and risk factors for Autoimmune hemolytic anemia pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Assosciate Editor(s)-In-Chief: Prashanth Saddala M.B.B.S; Shyam Patel [2], Irfan Dotani [3]
Overview
The pathophysiology of autoimmune hemolytic anemia is different for warm-antibody type and cold-antibody type anemia. The pathophysiology of warm-antibody type autoimmune hemolytic anemia involves the coating of red blood cells with IgG, followed by extravascular hemolysis by splenic macrophages. The pathophysiology of cold-antibody type autoimmune hemolytic anemia involves the coating of red blood cells with IgM, followed by intravascular hemolysis. The complement system has a significant role in autoimmune hemolytic anemia and involves the binding of classical complement proteins on the red blood cell surface, followed by cell lysis by the membrane attack complex. In summary, a variety of cell-mediated immunologic mechanisms underlie the pathophysiology of autoimmune hemolytic anemia.
Pathophysiology
Warm autoimmune hemolytic anemia
The pathophysiology of warm autoimmune hemolytic anemia involves immunoglobulin G (IgG) antibodies binding to red blood cells at a temperature of 37 degrees Celsius. [1] The designation of warm is based on the fact the optimal binding temperature is 37 degrees Celsius, or normal body temperature. The IgG antibodies are typically polyclonal, meaning that they recognize a variety of antigens.[2] Macrophages bind to the antibody-coated red blood cells via the Fc receptors and result in extravascular destruction. The Fc receptors include Fc-gammaRI (CD64), Fc-gammaRII (CD32), and Fc-gammaRIII (CD16). In 15-20% of cases, the autoantibody involved is IgA.[2] It has been shown that induction of autoimmune hemolytic anemia is controlled by an immunosuppressive population of T lymphocytes known as regulatory T cells.[1]
Cold autoimmune hemolytic anemia
The pathophysiology of cold autoimmune hemolytic anemia, or cold agglutinin disease, involves immunoglobulin M (IgM) antibodies binding to Ii carbohydrate antigens of red blood cells at a temperature of 3-5 degrees Celcius. Agglutination typically occurs in the distal aspects of the extremities, such as the fingers and toes, because these areas have the lowest temperature.[3] Clinical manifestations of this pathophysiology includes Raynaud's phenomenon and acrocyanosis.[3] The IgM molecules will trigger activation of the complement system, which results in red blood cell lysis.[3] When IgM-bound red blood cells circulate towards warmer areas of the body, such as the trunk, IgM will dissociate from the red blood cells and complement C3b will remain bound.
Role of the complement system
The complement system is partially involved in the pathophysiology of warm autoimmune hemolytic anemia. There is a stronger role for the complement system in certain types of autoimmune hemolytic anemia, such as paroxysmal cold hemoglobinuria, cold agglutinin disease, and cold agglutinin syndrome.[3] The complement system plays a role in both extravascular hemolysis and intravascular hemolysis in autoimmune hemolytic anemia.
- Complement activation by immunoglobulin subclasses: The immunoglobulin type that is most potent in activating complement is immunoglobulin M (IgM). However, IgM is not typically detected in the Coombs' test, so IgM-mediated hemolysis will likely manifest as a Coombs'-negative hemolytic anemia. Immunoglobulin G (IgG) can activate complement, and the different IgG subclasses have differentially ability to activate complement. IgG3, for example, is a more potent activator of complement than IgG1. IgG4 and immunoglobulin A (IgA) are unable to activate complement.[3]
- Extravascular hemolysis: The pathophysiology of extravascular hemolysis in autoimmune hemolytic anemia involves destruction of red blood cells outside the blood vessels and inside the liver and spleen. This is largely due to complement protein C3b-mediated phagocytosis of red blood cells. This process begins with the C3 convertase, which leads to production of complement protein C3b. This protein normally functions to opsonize bacteria and prevent infection, as part of the innate immune system. However, in pathological conditions such as autoimmunity, C3b binds to the surface of red blood cells. Opsonization by C3b triggers the macrophages of the reticuloendothelial system to phagocytose these opsonized cells via complement receptors on the surface of macrophages. This phagocytosis occurs extravascularly, typically in the liver or spleen. In some cases, ectoenzymes that are located on the surface of macrophages can perforate red blood cell membranes and create spherocytes.[3] When the amount of red blood cell membrane removed exceeds the intracellular volume removed, the biconcave disc shape becomes a spherocytic shape. This is the pathophysiologic basis for spherocytes in autoimmune hemolytic anemia.[3] Upon passage through the splenic vasculature, spherocytes can destroyed.
- Intravascular hemolysis: The pathophysiology of intravascular hemolysis in autoimmune hemolytic anemia involves destruction of red blood cells inside the blood vessels. This is largely due to activation of the terminal complement system.[2] This complement cascade begins with complement protein C5, which is activated to C5a and C5b by the C5 convertase. C5a is a potent anaphylactic molecule, C5b is a membrane-bound protein that binds to downstream complement molcules, such as C6 though C9. The union of C5b and C6 though C9 forms the membrane attack complex. This complex can exert direct cytotoxic activity via the creation of pores in red blood cell membranes, resulting in cell lysis intravascularly.[2]
Excess complement activation
- In some cases, the complement system can become activated very strongly, resulting in excess immune activation and red blood cell destruction, which can be lethal. This is due in part to a feedforward loop or positive feedback system, in which activation of the initial components of the complement cascade triggers activation of additional complement components.[2]
References
- ↑ 1.0 1.1 Mqadmi A, Zheng X, Yazdanbakhsh K (2005). "CD4+CD25+ regulatory T cells control induction of autoimmune hemolytic anemia". Blood. 105 (9): 3746–8. doi:10.1182/blood-2004-12-4692. PMC 1895013. PMID 15637139.
- ↑ 2.0 2.1 2.2 2.3 2.4 Berentsen S (2015). "Role of Complement in Autoimmune Hemolytic Anemia". Transfus Med Hemother. 42 (5): 303–10. doi:10.1159/000438964. PMC 4678321. PMID 26696798.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 Berentsen S, Sundic T (2015). "Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy". Biomed Res Int. 2015: 363278. doi:10.1155/2015/363278. PMC 4326213. PMID 25705656.